Edward Ryan, PhD
Associate Clinical ProfessorAbout
Research
Publications
2024
Antibiotic resistance and serotype distribution of Shigella strains in Bangladesh over the period of 2014-2022: evidence from a nationwide hospital-based surveillance for cholera and other diarrheal diseases.
Afrad M, Islam M, Begum Y, Saifullah M, Ahmmed F, Khan Z, Habib Z, Alam A, Shirin T, Bhuiyan T, Ryan E, Khan A, Qadri F. Antibiotic resistance and serotype distribution of Shigella strains in Bangladesh over the period of 2014-2022: evidence from a nationwide hospital-based surveillance for cholera and other diarrheal diseases. Microbiology Spectrum 2024, e0073924. PMID: 39540737, DOI: 10.1128/spectrum.00739-24.Peer-Reviewed Original ResearchAntimicrobial resistance patternsAntibiotic resistanceNalidixic acidResistance patternsAntibiotic susceptibility testingDisc diffusion methodStool specimensLevels of resistance to ciprofloxacinResistant to ciprofloxacinDiarrheal disease surveillanceQuinolone class of antibioticsClasses of antibioticsShigella strainsSerotype 2aShigella sonneiMonitoring of drug resistanceSusceptibility testingVaccine clinical trialsAcute watery diarrheaHospital-based surveillanceDiffusion methodIntermediate susceptibilityMultidrug resistanceSerotype distributionImproved hygieneReturn-to-Play After Plasmodium falciparum Malaria in a Professional American Football Player
Mun J, Ryan E, Whalen J, Martin S. Return-to-Play After Plasmodium falciparum Malaria in a Professional American Football Player. JBJS Case Connector 2024, 14: e24.00457. PMCID: PMC11581430, DOI: 10.2106/jbjs.cc.24.00457.Peer-Reviewed Original ResearchPlasmodium falciparum malariaPersistent splenomegalyHigh-grade feverProfessional American football playersAmerican football playersFalciparum malariaFootball playersPatient's symptomsCollision sport athletesMalariaEmergency departmentReturn-to-playBlood smearsHospital admissionRisk of deconditioningSplenomegalyNoncontact activityPatientsSport athletesSymptomsWeeksPlasmodiumOn-fieldFeverSmearsDevelopment of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge
Kelly M, Janardhanan J, Wagh C, Verma S, Charles R, Leung D, Kamruzzaman M, Pansuriya R, Chowdhury F, Vann W, Kaminski R, Khan A, Bhuiyan T, Qadri F, Kováč P, Xu P, Ryan E. Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge. Vaccine 2024, 42: 126263. PMID: 39217775, PMCID: PMC11409015, DOI: 10.1016/j.vaccine.2024.126263.Peer-Reviewed Original ResearchS. flexneri 6O-specific polysaccharideS. flexneri 3aShigella flexneri 2aShigella flexneri 6Component of lipopolysaccharideSerotype-specific monoclonal antibodiesS. sonneiShigella speciesFlexneri 2aShigella infectionShigella vaccineCarrier proteinHeavy chainBactericidal antibody responsesShigellaShigellosisVaccinated miceConjugate vaccineSerum of humansIgG responsesImmune responseLethal challengeAntibody responseIgM responseDeterminants of immune responses predictive of protection against shigellosis in an endemic zone: a systems analysis of antibody profiles and function
Bernshtein B, Kelly M, Cizmeci D, Zhiteneva J, Macvicar R, Kamruzzaman M, Bhuiyan T, Chowdhury F, Khan A, Qadri F, Charles R, Xu P, Kováč P, Clarkson K, Kaminski R, Alter G, Ryan E. Determinants of immune responses predictive of protection against shigellosis in an endemic zone: a systems analysis of antibody profiles and function. The Lancet Microbe 2024, 5: 100889. PMID: 39116906, PMCID: PMC11488819, DOI: 10.1016/s2666-5247(24)00112-5.Peer-Reviewed Original ResearchFlexneri 2aShigella infectionO-specific polysaccharideS sonneiShigella flexneri 2aEndemic settingsAntibody responseInnate immune cell activationProduction of reactive oxygen speciesShigella sonneiFunctional antibody responsesNon-endemic populationCorrelates of protectionShigellaImmune cell activationShigella vaccineNon-endemic settingsReceptor binding profileReactive oxygen speciesSerum samplesAntibody-mediated activationHigh-burden settingsSonneiPredictive of protectionAntibody-mediated complement depositionVibrio cholerae O1 experiences mild bottlenecks through the gastrointestinal tract in some but not all cholera patients
Lypaczewski P, Chac D, Dunmire C, Tandoc K, Chowdhury F, Khan A, Bhuiyan T, Harris J, LaRocque R, Calderwood S, Ryan E, Qadri F, Shapiro B, Weil A. Vibrio cholerae O1 experiences mild bottlenecks through the gastrointestinal tract in some but not all cholera patients. Microbiology Spectrum 2024, 12: e00785-24. PMID: 38916318, PMCID: PMC11302224, DOI: 10.1128/spectrum.00785-24.Peer-Reviewed Original ResearchGenetic diversityVibrio cholerae</i> O1Short-read dataLong-read sequencingDiarrheal disease choleraReduced genetic variationBacterial population sizeSingle-nucleotide variationsPangenome analysisGene presence/absencePilus operonPopulation bottlenecksDisease choleraMild bottleneckGene presenceGut colonizationGenetic variationAdaptive mutationsGenomeCholera patientsPopulation sizeGut resultsSites of active infectionGutStool samplesModeling approaches to inform travel-related policies for COVID-19 containment: A scoping review and future directions
Koiso S, Gulbas E, Dike L, Mulroy N, Ciaranello A, Freedberg K, Jalali M, Walker A, Ryan E, LaRocque R, Hyle E. Modeling approaches to inform travel-related policies for COVID-19 containment: A scoping review and future directions. Travel Medicine And Infectious Disease 2024, 62: 102730. PMID: 38830442, DOI: 10.1016/j.tmaid.2024.102730.Peer-Reviewed Original ResearchCoding-complete genomes of 18 SARS-CoV-2 Omicron JN.1, JN.1.4, and JN.1.11 sub-lineages in Bangladesh
Tahsin A, Hasan M, Rahman S, Jubair M, Afrad M, Khan M, Alam S, Begum M, Karim Y, Mukta S, Habib M, Alam A, Chowdhury E, Rahman R, Ryan E, Shirin T, Rahman M, Qadri F. Coding-complete genomes of 18 SARS-CoV-2 Omicron JN.1, JN.1.4, and JN.1.11 sub-lineages in Bangladesh. Microbiology Resource Announcements 2024, 13: e00135-24. PMID: 38656213, PMCID: PMC11237443, DOI: 10.1128/mra.00135-24.Peer-Reviewed Original ResearchCholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants
Dash P, Hakim A, Akter A, Banna H, Kaisar M, Aktar A, Jahan S, Ferdous J, Basher S, Kamruzzaman M, Chowdhury F, Akter A, Tauheed I, Weil A, Charles R, Calderwood S, Ryan E, LaRocque R, Harris J, Bhuiyan T, Qadri F. Cholera toxin and O-specific polysaccharide immune responses after oral cholera vaccination with Dukoral in different age groups of Bangladeshi participants. MSphere 2024, 9: e00565-23. PMID: 38391226, PMCID: PMC10964428, DOI: 10.1128/msphere.00565-23.Peer-Reviewed Original ResearchB cell responsesMemory B cell responsesClass-switched antibody responsesOral cholera vaccineAntibody responseImmune responseCholera toxin B subunitCholera vaccineToxin B subunitAge groupsAnti-OSPOlder childrenPrevent choleraIgG antibody responsesYoung childrenB subunitVaccine seriesSignificant IgAIgM responseWhole-cellOlder vaccineesCholera toxinIgAVaccineIgG
2023
Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations
Akhtar M, Islam M, Khaton F, Soltana U, Jafrin S, Rahman S, Tauheed I, Ahmed T, Khan I, Akter A, Khan Z, Islam M, Khanam F, Biswas P, Ahmmed F, Ahmed S, Rashid M, Hossain M, Alam A, Alamgir A, Rahman M, Ryan E, Harris J, LaRocque R, Flora M, Chowdhury F, Khan A, Banu S, Shirin T, Bhuiyan T, Qadri F. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Frontiers In Immunology 2023, 14: 1309997. PMID: 38173725, PMCID: PMC10763240, DOI: 10.3389/fimmu.2023.1309997.Peer-Reviewed Original ResearchConceptsFuture vaccination strategiesIgG responsesVaccination strategiesVaccine typesImmunological toleranceImmune responseMRNA dosesSpecific IgG antibody responseIgG subclass analysisRobust IgG responseChAdOx1 nCoV-19IgG antibody responsePrimary IgG responseSARS-CoV-2 variantsHumoral immune responseMRNA vaccine dosesCOVID-19 vaccinationNumber of dosesSARS-CoV-2 spike receptorBooster dosesBooster vaccinationIgG4 levelsIgG4 responsesMRNA vaccinationIgG levels
2006
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.
HILL D, BAIRD J, PARISE M, LEWIS L, RYAN E, MAGILL A. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. American Journal Of Tropical Medicine And Hygiene 2006, 75: 402-15. PMID: 16968913, DOI: 10.4269/ajtmh.2006.75.402.Peer-Reviewed Original ResearchConceptsP. ovale malariaPrimary prophylaxisAdult doseRelapses of Plasmodium vivaxAnti-relapse therapyRecommended adult doseMalaria speciesP. vivaxPlasmodium vivaxBlood schizonticideDeficiency of G6PDLiver stagesMalarious regionsRadical cureEstablished infectionPrevent relapseClinical trialsMalariaProphylaxisPrimaquineDosePrimaquine phosphateGlucose-6-phosphate dehydrogenaseDaysGlucose-6-phosphate